Literature DB >> 27873015

Muscarinic receptor binding changes in postmortem Parkinson's disease.

Caitlin McOmish1,2, Geoff Pavey3, Catriona McLean4, Malcolm Horne3, Brian Dean3, Elizabeth Scarr3.   

Abstract

Parkinson's disease (PD) is a devastating disorder, affecting approximately 2% of people aged 60 and above. It is marked by progressive neurodegeneration that has long been known to impact dopaminergic cells and circuits, but more recently the acetylcholine system has also been implicated in the complex aetiology and symptomatology of the disease. While broad changes in cholinergic markers have been described, insight into the contribution of specific acetylcholine receptors is less clear. To address this important unknown, in this study we performed [3H] pirenzepine, [3H] 4DAMP, and [3H] AF-DX 384 in situ radioligand binding on postmortem tissues from Brodmann's area 6, 9, 46, and the caudate putamen, from PD and matched controls to detect muscarinic M1, M3, and M1/2/4 receptors, respectively. We found no difference in [3H] pirenzepine binding between PD and controls across all regions assessed. [3H] 4DAMP binding was found to be higher in PD CPu and BA9 than in controls. [3H] AF-DX 384 was higher in BA9 of PD compared with controls. In sum, we show selective increase in M3 receptors in cortical and subcortical regions, as well as increased M2/M4 in cortical area BA9, which together support a role for cholinergic dysfunction in PD.

Entities:  

Keywords:  Acetylcholine; Human; Muscarinic receptor; Parkinson’s disease; Postmortem

Mesh:

Substances:

Year:  2016        PMID: 27873015     DOI: 10.1007/s00702-016-1629-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

1.  Motor perseveration is an early sign of Parkinson's disease.

Authors:  D Stoffers; H W Berendse; J B Deijen; E C Wolters
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

2.  Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.

Authors:  Weilie Zhang; Masahisa Yamada; Jesus Gomeza; Anthony S Basile; Jürgen Wess
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

Review 3.  Antimuscarinic drugs in the treatment of movement disorders.

Authors:  S Fahn; R Burke; Y Stern
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

Review 4.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 5.  Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

Authors:  Elizabeth Scarr; Brian Dean
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

6.  Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease.

Authors:  K W Lange; F R Wells; M N Rossor; P Jenner; C D Marsden
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

7.  Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons.

Authors:  E J Mufson; L N Presley; J H Kordower
Journal:  Brain Res       Date:  1991-01-18       Impact factor: 3.252

8.  Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

Authors:  E T Tzavara; F P Bymaster; C C Felder; M Wade; J Gomeza; J Wess; D L McKinzie; G G Nomikos
Journal:  Mol Psychiatry       Date:  2003-07       Impact factor: 15.992

9.  Perseverative motor behaviour in Parkinson's disease.

Authors:  G Ebersbach; H Hättig; L Schelosky; J Wissel; W Poewe
Journal:  Neuropsychologia       Date:  1994-07       Impact factor: 3.139

10.  Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.

Authors:  J N Joyce
Journal:  Brain Res       Date:  1993-01-08       Impact factor: 3.252

View more
  3 in total

1.  Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection.

Authors:  Teresa Mann; Karl Zilles; Felix Klawitter; Markus Cremer; Alexander Hawlitschka; Nicola Palomero-Gallagher; Oliver Schmitt; Andreas Wree
Journal:  Front Neuroanat       Date:  2018-08-10       Impact factor: 3.856

2.  DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats.

Authors:  Puneet K Sharma; Lisa Wells; Gaia Rizzo; Joanna L Elson; Jan Passchier; Eugenii A Rabiner; Roger N Gunn; David T Dexter; Ilse S Pienaar
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

3.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.